South Korea on Wednesday approved the use of SKYCovione, the country's first homegrown COVID-19 vaccine developed by SK Bioscience Co., taking a major step toward achieving vaccine sovereignty in the fight against the pandemic.
The Ministry of Food and Drug Safety (MFDS) said it approved the use of SKYCovione, also known as GBP510, through consultations of the ministry's Final Inspection Committee, following an "item approval" recommendation by MFDS' Central Pharmaceutical Affairs Council on Monday, Yonhap news agency reported.
SKYCovione is the country's first homegrown vaccine to have successfully completed all three phases of its clinical trial. SK Bioscience conducted a phase-three clinical trial on some 4,000 adults in six countries -- Thailand, Vietnam, New Zealand, Ukraine, the Philippines and South Korea.
It is a recombinant-protein vaccine based on novel two-component nanoparticles that can maximize the immune effect. It was jointly developed with the Institute for Protein Design at the University of Washington.
The vaccine has been designed for recipients to receive two doses in a four-week interval.
--IANS
int/svn/
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
You’ve hit your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Quarterly Starter
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Access to Exclusive Premium Stories Online
Over 30 behind the paywall stories daily, handpicked by our editors for subscribers


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app